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increased mid-term mortality after TAVI. This association with decreased survival is 
poorly explained. We sought to analyse the impact of AR on mortality after TAVI as 
a function of baseline NT-proBNP (NTBNP). 
Methods: We included 222 consecutive patients from our single centre registry, all 
implanted with the Edwards valve, via the transfemoral route. AR severity was evaluated 
by transthoracic echocardiography. NTBNP was measured 24 hours before implantation 
and patients were divided in 2 groups according to the median NTBNP value.
Results: Mean age was 83.6±7 years and 131 (59%) were women. Patients 
with low NTBNP had higher left ventricular ejection fraction: 62±11% vs 49±17%, 
p<0.001, smaller telediastolic: 52 mm (48 - 56) vs 57 mm (48 - 61), p=0.002 and 
telesistolic diameters: 32 mm (28 - 36) vs 39 mm (33 - 48), p<0.001, but a similar 
mean aortic gradient: 45±14 mmHg vs 46±20 mmHg, p=0.75. Baseline AR ≥2 was 
less frequent in the low NTBNP group: 26% vs 44%, p=0.005. After TAVI, AR ≥2 
occurred in 27% and was signifi cantly associated with increased 1-year mortality only 
in the low NTBNP group (Figure).
Conclusion: More than mild AR after TAVI was associated with increased 
1-year mortality only in patients with low baseline NTBNP. Our data suggest that the 
impact of AR after TAVI is absent in patients with remodelled ventricles and more 
severe baseline AR. 
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Baseline NT-proBNP and the impact of more than mild aortic regurgitation 
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Background: Aortic regurgitation (AR) is an important complication of trans-
catheter aortic valve implantation (TAVI) and even moderate AR is associated with 
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Figure – Abstract 213 – Mortality at 1 year stratifi ed by AR and NTBNP
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Is pre-TAVI EP study useful to predict risk of post-procedure pacemaker 
implantation?
Sara Thomann, Thien Tri Cung, Jean Marc Davy, Chirstophe Piot, Jean-Luc 
Pasquie, Bernard Albat, Florence Leclercq, Frederic Cransac, Francois Massin, 
Omar Alfalasi
CHU Arnaud de Villeneuve, cardiologie sud, Montpellier cedex 5, France
Introduction: Recent studies have shown that transcatheter aortic valve implan-
tation (TAVI) can induced severe conduction disorders. However, the usefulness and 
the time of electrophysiology (EP) study is still unclear. 
Methods: This single-center prospective study took place from December 2010 
to Mai 2012 and included 81 patients. An ECG was realized before, immediately after 
and 24 hours after the procedure along with the registry of the electric modifi cations 
during the procedure. EP study was realized before and/or after TAVI. A follow up at 
one month with an ECG and clinical advents has been realized.
Results: Out of the 81 patients, 74% were implanted with an Edwards valve and 
26% with a Corevalve. The pacemaker implantation rate was respectively 16% and 
35% (p=0.03). 30% of them underwent an EP study before and after TAVI. Risk factors 
correlated to a higher risk of permanent pacing are male gender (p=0.04), pre-existing 
right bundle branch block (p<0.001), PR>200 ms (p=0.008), QRS width >120 ms 
(p=0.01), left axis deviation (p=0.003), larger valve diameter (26mm vs 24mm; 
p=0.04), prolonged HV interval (67.7 vs 57 ms; p=0.01), Corevalve (p=0.03), and 
renal insuffi ciency (p=0.04). The HV interval was signifi cantly prolonged after TAVI 
(58.9 ms to 68.8ms, p=0.007). None of the patients with an initial HV interval below 
60ms was implanted with a pacemaker. Furthermore, no patient with a pre-TAVI 
QRS width below 120 ms and a HV interval below 65 ms necessitated pacemaker 
implantation with a 100% positive predictive value.
Conclusions: Some clinical and EP factors seem to be identifi ed as risk factors 
for the implantation of a pacemaker post TAVI, such as male gender, a pre-TAVI wide 
QRS particularly RBBB, a prolonged PR interval, chronic renal failure, a larger valve 
diameter and the use of a Corevalve. QRS width combined to a pre-TAVI EP study 
appears to predict the risk of pacemaker implantation. However, these results need 
to be confi rmed by larger studies.
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Background: Transcatheter aortic valve replacement (TAVR) is a new treatment 
alternative for patients with severe symptomatic aortic stenosis (AS) who are poor 
candidates for surgical aortic valve replacement. 
Objective: To determine the survival of patients with severe symptomatic AS 
who were referred for inclusion in French TAVR trials using the Edwards SAPIEN 
(Edwards Lifescience, Irvine, CA) valve from April 1, 2006 to November 30, 2007, 
but who have not undergone the procedure.
Methods: 140 patients with severe symptomatic AS were referred for possible 
TAVR to Rouen University Hospital. Of these Pts, only 38 were implanted, while 
51 were excluded and 51 were awaiting implantation. Those 102 Pts represented 
our study group. Demographic, clinical and hemodynamic variables were assessed. 
Survival, cause of death, and factors predicting these outcomes were analyzed. Only 
2 Pts were lost for follow-up.
Results: One hundred and two patients (49 males and 53 females), mean age 
85 years, were included and followed. During the follow-up period, fi nally6 patients 
on the waiting list underwent TAVR, and 3 had surgical aortic valve replacement. 
Patients excluded from TAVR (n=51) had an observed median survival of 285 days 
(124-585). Patients waiting for valve implantation but who have not received TAVR 
or surgery (n=42), had a median survival of 609 days (383-763). The difference in 
survival between the two groups was not statistically signifi cant (p=0,546, Log Rank). 
Mortality was associated with a higher logistic EuroSCORE (>25%, p=0.0027, >20%, 
p=0.075). Overall survival at 1 year was 67% in the waiting list (vs 45% for excluded 
patients, NS), and 22% at 3 years (vs 21%, NS).
Conclusion: Patients considered for TAVR have a high rate of early mortality 
without treatment. Risk stratifi cation may help to select patients for TAVR. 
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0 52
Pts excluded for TAVR protocol
Weeks since admission
C
u
m
u
la
te
d
 p
ro
b
ab
ili
ty
Pts on the waiting list
104 156 208 260
Figure – Abstract 371 – Overall survival of patients on the waiting
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Balloon aortic valvuloplasty in the era of transcatheter aortic valve repla-
cement: acute and long-term outcomes
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Background: The use of balloon aortic valvuloplasty (BAV) has resurged since 
the development of trans-catheter aortic valve replacement (TAVR). The aim of our 
study was to determine the procedural and long-term outcomes of patients treated by 
BAV in the early TAVR era. 
Methods: From 2005 to 2008, 323 consecutive patients presenting with severe 
aortic stenosis were treated by BAV in our institution. 
Results: Mean age and logistic EuroSCORE were 80.5±9.9 years and 28.7±12.5 %, 
respectively. The effective orifi ce area increased from 0.68±0.25 to 1.12±0.39 cm2 
(p<0.001) after BAV. In-hospital major complications occurred in 26 patients (8.0%), 
with a mortality rate of 2.5%. Eighty-fi ve patients (26.3%) were bridged to surgical 
aortic valve replacement (SAVR, 9.6%) or TAVR (16.7%). Twenty-eight patients 
(8.7%) had at least one repeat BAV. Two hundred and ten patients (65%) received 
only medical therapy post-BAV. Mean duration of follow-up was 20.7±20.0 months. 
Kaplan-Meier analysis demonstrated that survival after single BAV was poor. Patients 
treated by BAV followed by SAVR or TAVR had the highest long-term survival 
rate. Redo-BAV presented a signifi cant survival advantage compared to single BAV. 
Multivariate analysis revealed that logistic EuroSCORE, severe aortic regurgitation and 
stroke complications post-BAV were independent predictors of mortality. In contrast, 
bridge to SAVR or TAVR, as well as redo BAV were independent predictors of survival. 
Conclusions: The results of our study suggest that BAV is an acceptable bridge to 
SAVR or TAVR in a very high-risk population not immediately suitable for defi nitive 
therapy. Interestingly, redo BAV may be proposed as an alternative strategy in patients 
with persistent contraindications to SAVR and TAVR.
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Performance analysis of EuroSCORE II compared to the original logistic 
EuroSCORE and STS scores for predicting 30-day mortality after trans-
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The original EuroSCORE has been recently updated by EuroSCORE II to 
optimize its effi cacy in cardiac surgery but its performance has never been evaluated 
for predicting 30-day mortality in patients undergoing transcatheter aortic valve 
replacement (TAVR). Consecutive patients (n=250) treated by TAVR were included for 
analysis. Transapical (TA) access was used in 60 patients, while 190 procedures were 
performed using a transfemoral (TF) approach. Calibration (risk-adjusted mortality 
ratio, RAMR) and discrimination (c- and u-statistics) were calculated for the logistic 
EuroSCORE, EuroSCORE II, and Society of Thoracic Surgeons (STS) scores for 
predicting 30-day mortality. The observed mortality was 7.6% in the overall population 
(6.3% and 11.7% for the TF and TA cohorts, respectively). Predicted mortality was 
22.6±12.8 % by logistic EuroSCORE, 7.7±5.8% by EuroSCORE II, and 7.3±4.1 % 
by STS score. RAMR was 0.34 (95% CI 0.10-0.58) for logistic EuroSCORE, 0.99 
(95% CI 0.29-1.69) for EuroSCORE II, and 1.05 (95% CI 0.30-1.79) for STS score. A 
moderate discrimination was observed with EuroSCORE II [0.66 (95% CI 0.52-0.79), 
p=0.02] as compared to logistic EuroSCORE [0.63 (95% CI 0.51-0.76), p=0.06] and 
STS [0.58 (95% CI 0.43-0.73), p=0.23] scores without signifi cant difference among 
the 3 risk-scores. Discrimination was slightly better in the TF as compared to the 
TA cohort with the 3 risk-scores. In conclusion, EuroSCORE II and STS scores are 
better calibrated than the logistic EuroSCORE but have moderate discrimination for 
predicting 30-day mortality after TAVR. 
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From June 2010 to June 2011, 56 patients (23 males) were prospectively 
included. Mean age was 84±5 years and mean logistic EuroSCORE was 20.4±2.8%. 
Valve prosthesis (Edwards Sapien/Sapien XT) was implanted using trans-femoral 
approach in 44 (79%) and transapical approach in others. Comprehensive geriatric 
assessment using the following scores was performed before implantation and 
at 6-month after TAVI: Geriatric Depression Scale (GDS), Mini Mental State 
Examination (MMSE), Activities of daily Living (ADL), Instrumental Activities 
of daily Living (IADL), Timed up and go test (TUG), Charlson test, Vulnerability 
Elders Survey (VES 13). 
TAVI was successfully performed in 53 (95%) patients. At 6 month, survival rate 
was 81% and there was a marked improvement in hemodynamics and symptoms. 
On echocardiography, mean gradient had decreased from 48±18 to 9.8±0.7 mm Hg, 
(p<0.01); aortic valve area had increased from 0.7±0.08 to 1.8±0.29 cm2, (p<0.01) 
and there was a signifi cant change in New York Heart Association class (p<0.01). 
There was no signifi cant changes in autonomy and dependence scores at 6-month 
for GDS (0.8±1.2 vs 1.3±1.3, p=NS); MMSE (23.7±4.4 vs 22.9±4.2, p=NS); ADL 
(5.3±1.4 vs 5.3±0.7, p=NS); IADL (5.2±2.2 vs 4.8±2.4, p=NS); TUG (25.3±16.6 vs 
26.1±15.8, p=NS). 
Only VES 13 had increased (5±0.7 vs 6.4±2.8, p=0.03) indicating vulnerable 
patients.
Our results demonstrate a marked and signifi cant clinical benefi t of TAVI at 
6 months without autonomy and dependence impairment in Pts with severe symptomatic 
aortic valve stenosis.
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Severe aortic stenosis at the time of percutaneous Transarterial Aortic 
Valve Implantation, and new syndromes “normal fl ow-low gradient” and 
“paradoxical low fl ow-low gradient”
Stéphanie Mouton (1), David Montaigne (2) 
(1) CHRU Lille, soins intensifs cardiologiques, Lille, France – (2) CHRU Lille, 
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Paradoxical low gradient aortic stenosis is a new entity for which the optimal 
management approach remains debated. The aim was to show the heterogeneity 
of practices due to the lack of recommendations concerning the management of 
patients having a severe aortic stenosis (SAS). In 2012, a survey was conducted in 
all cardiologists (313) of the “Nord-Pas-de-Calais” region (France). A questionnaire 
with fi ve brief clinical cases was used to ask proposed management. The exercice 
test was retained by 52.7% of the practitioners for the asymptomatic SAS. According 
to guidelines, 91.4% of the cardiologists proposed surgical treatment for the 
symptomatic SAS. 81.5% of the practitioners performed a stress echocardiography 
using Dobutamine for patients having a low gradient aortic stenosis with a 
depressed left ventricular function. Surgical treatment was considered in 58.9% 
of cases for patients having a paradoxical low fl ow/low gradient aortic stenosis 
and in 22.8% of cases for the normal fl ow/low gradient aortic stenosis. Contrary 
to normal fl ow/low gradient, paradoxical low fl ow/low gradient aortic stenosis was 
complementary explored in less than one third of cases and proposed examinations 
were often inappropriate. 
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Decline of platelet count following TAVI: incidence, mechanism and prognostic 
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Background: Decrease in blood platelet count has been described following 
percutaneous coronary intervention (PCI) and surgical valve replacement, while no 
study has been performed in the setting of transcatheter aortic valve implantation 
(TAVI).We aimed to address the incidence, mechanism and impact of blood platelet 
count decrease following TAVI.
Methods: One hundred forty four consecutive patients (84±7 years old, 64 men) 
with severe symptomatic aortic stenosis who underwent TAVI between December 
2007 and July 2011 were enrolled in the study. Blood platelet count was recorded 
before and after aortic valve implantation. Blood platelet decrease was compared to 
in-hospital MACE defi ned by death, stroke and major or life threatening bleeding.
Results: Blood platelet decrease occurred in all patients but one. The percentage of 
platelet decrease averaged 34±15% and was 24% greater than blood protein decrease. 
Decrease in platelet was associated with higher rate of prosthesis migration, longer 
X-Ray and procedure time and higher contrast amount (230±128 mL for the 3rdtertile 
vs 170±77 mL for 2nd and 1st tertile, p=0.0006), while no association was observed with 
changes in bilirubin. In hospital MACE (n=50, 35%) were more observed in patients 
with severe platelet count decrease (21% for the 1sttertile, 35% for the 2nd tertile, 
and 48% for the 3rdtertile, p=0.02). Finally, the percentage of blood platelet count 
decrease was the only predictor of in hospital MACE (38±14% vs 32±16%, p=0.02).
Conclusion: Decline in platelet count is a common phenomenon following TAVI 
and its severity is associated with worse outcome after TAVI.
321
Comprehensive geriatric assessment in transcatheter aortic valve implantation 
patients
Segolene Rouffi ac (1), Fanny Bouchinet (2), Matthieu Godin (2), Camille 
Hauville (2), Bogdan Borz (2), Philippe Chassagne (1), Christophe Tron (2), 
Hélène Eltchaninoff (1) 
(1) CHU Charles Nicolle, Rouen, France – (2) CHU Charles Nicolle, cardiologie, 
Rouen, France
For more than ten years, an alternative therapy for inoperable or high risk 
symptomatic patients (Pts) with severe aortic stenosis is developed: transcatheter 
aortic valve implantation (TAVI). However, in elderly Pts optimal management of 
aortic valve depends on dependence and autonomy improvement. The aim of our 
study is to evaluate changes in geriatrics autonomy and dependence using specifi c 
geriatric scores in Pts undergoing TAVI. 
